Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use

Abstract

Keywords

dupilumab conjunctivitis ocular surface disorders keratitis blepharitis red eye dry eye atopic dermatitis clinical practice long-term

Get full access to this article

View all access options for this article.

References

Simpson

EL.

Bieber

Guttman-Yassky

et al. Two phase 3 trials of Dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.doi:10.1056/NEJMoa1610020

http://www.ncbi.nlm.nih.gov/pubmed/27690741

Blauvelt

. Dual Inhibition of IL-12/IL-23 and Selective Inhibition of IL-23 in Psoriasis. In: Yamauchi

PS.

, ed. Biologic and Systemic Agents in Dermatology. Springer International Publishing; 2018:123-131.

de Bruin-Weller

Thaçi

Smith

et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (liberty AD CAFÉ. Br J Dermatol. 2018;178(5):1083-1101.doi:10.1111/bjd.16156

http://www.ncbi.nlm.nih.gov/pubmed/29193016

Wollenberg

Ariens

Thurau

van Luijk

Seegräber

de Bruin-Weller

. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment. J Allergy Clin Immunol Pract. 2018;6(5):1778-1780.doi:10.1016/j.jaip.2018.01.034

http://www.ncbi.nlm.nih.gov/pubmed/29432961

Gooderham

McDonald

Papp

. Diagnosis and management of conjunctivitis for the dermatologist. J Cutan Med Surg. 2018;22(2):200-206.doi:10.1177/1203475417743233

http://www.ncbi.nlm.nih.gov/pubmed/29191053